Table 6.
PCP-altered genes were normalized by coadministration of OLZ and fulfilled three criteria: significantly dysregulated in PCP-versus VEH-administered animals, significantly altered in the same direction between PCP- and PCP + OLZ-administered animals, and showed no significant difference in expression between PCP+ OLZ- and VEH-administered animals
| Gene symbol | Gene title | PCP vs. VEH |
PCP vs. PCP/OLZ |
PCP/OLZ vs. VEH |
|||
|---|---|---|---|---|---|---|---|
| p value | FC | p value | FC | p value | FC | ||
| ACTB | actin, beta | 4.5E-04 | −1.24 | 3.3E-06 | −1.36 | 8.8E-02 | 1.10 |
| ACYP1 | acylphosphatase 1, erythrocyte (common) type | 3.0E-02 | −1.16 | 5.0E-02 | −1.15 | 8.4E-01 | −1.01 |
| ATP1A3 | ATPase, Na+/K+ transporting, alpha 3 polypeptide | 8.0E-04 | –1.22 | 5.5E-04 | –1.23 | 8.4E-01 | 1.01 |
| ATP2A2 | ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 | 1.2E-02 | –1.21 | 4.5E-02 | –1.16 | 5.7E-01 | –1.04 |
| ATP2B2 | ATPase, Ca++ transporting, plasma membrane 2 | 1.4E-04 | –1.28 | 6.3E-04 | –1.25 | 6.5E-01 | –1.03 |
| ATP6V1A | ATPase, H+ transporting, lysosomal 70 kDa, V1 subunit A | 1.4E-03 | –1.28 | 2.2E-02 | –1.19 | 3.0E-01 | –1.07 |
| C1orf61 | chromosome 1 open reading frame 61 | 9.2E-03 | –1.19 | 3.6E-02 | –1.15 | 5.8E-01 | –1.03 |
| CACNB4 | calcium channel, voltage-dependent, beta 4 subunit | 1.1E-03 | –1.25 | 1.7E-02 | –1.18 | 3.1E-01 | –1.07 |
| CAMK2G | calcium/calmodulin-dependent protein kinase II gamma | 3.4E-02 | –1.13 | 3.0E-02 | –1.14 | 9.2E-01 | 1.01 |
| CBX3 /// LOC644101 | chromobox homolog 3 (HP1 gamma homolog, Drosophila) /// similar to chromobox homolog | 2.2E-03 | –1.24 | 6.4E-03 | –1.21 | 7.2E-01 | –1.02 |
| CNTN1 | Contactin 1 | 2.2E-05 | –1.38 | 6.5E-04 | –1.29 | 2.8E-01 | –1.07 |
| CSNK1G2 | casein kinase 1, gamma 2 | 3.7E-02 | –1.16 | 4.7E-02 | –1.16 | 9.5E-01 | –1.00 |
| CTBP1 | C-terminal-binding protein 1 | 5.9E-03 | –1.22 | 2.7E-02 | –1.18 | 5.5E-01 | –1.04 |
| CYP2A13 | cytochrome P450, family 2, subfamily A, polypeptide 13 | 4.3E-02 | –1.14 | 4.6E-02 | –1.14 | 1.0E+00 | 1.00 |
| GABRB3 | gamma-aminobutyric acid (GABA) A receptor, beta 3 | 2.8E-04 | –1.29 | 1.6E-02 | –1.17 | 1.4E-01 | –1.09 |
| GAPDH | glyceraldehyde-3-phosphate dehydrogenase | 5.2E-03 | –1.19 | 6.2E-05 | –1.32 | 1.0E-01 | 1.10 |
| GDI2 | GDP dissociation inhibitor 2 | 2.4E-03 | –1.21 | 9.7E-03 | –1.18 | 6.2E-01 | –1.03 |
| KCNAB2 | potassium voltage-gated channel, shaker-related subfamily, beta member 2 | 7.4E-03 | –1.17 | 9.3E-02 | –1.10 | 2.7E-01 | –1.06 |
| KLHDC3 | kelch domain containing 3 | 2.5E-03 | –1.23 | 5.2E-03 | –1.22 | 8.2E-01 | –1.01 |
| MAP2 | microtubule-associated protein 2 | 1.1E-02 | –1.24 | 3.0E-03 | –1.30 | 5.7E-01 | 1.05 |
| MAT2A | methionine adenosyltransferase II, alpha | 2.4E-02 | –1.17 | 2.7E-02 | –1.17 | 9.8E-01 | –1.00 |
| MBP | myelin basic protein | 1.3E-03 | –1.28 | 4.3E-02 | –1.17 | 1.7E-01 | –1.10 |
| MEF2C | myocyte enhancer factor 2C | 1.2E-03 | –1.25 | 4.7E-03 | –1.21 | 6.4E-01 | –1.03 |
| NF2 | neurofibromin 2 (merlin) | 4.7E-02 | –1.13 | 1.7E-02 | –1.17 | 6.1E-01 | 1.03 |
| NOMO1 /// NOMO2 /// NOMO3 | NODAL modulator 1 /// NODAL modulator 2 /// NODAL modulator 3 | 1.3E-02 | –1.15 | 1.7E-02 | –1.15 | 9.6E-01 | –1.00 |
| NRCAM | neuronal cell adhesion molecule | 1.2E-03 | –1.26 | 2.0E-02 | –1.18 | 2.8E-01 | –1.07 |
| PAK1 | p21 protein (Cdc42/Rac)-activated kinase 1 | 1.2E-03 | –1.33 | 6.7E-03 | –1.27 | 5.5E-01 | –1.05 |
| PLD3 | phospholipase D family, member 3 | 1.1E-02 | –1.19 | 6.5E-03 | –1.21 | 7.9E-01 | 1.02 |
| PLP1 | proteolipid protein 1 | 7.6E-03 | –1.21 | 9.3E-03 | –1.21 | 9.7E-01 | –1.00 |
| PRKACB | protein kinase, cAMP-dependent, catalytic, beta | 4.2E-03 | –1.19 | 4.6E-03 | –1.19 | 9.9E-01 | 1.00 |
| PRKCG | protein kinase C, gamma | 2.9E-03 | –1.19 | 6.9E-04 | –1.23 | 5.5E-01 | 1.03 |
| PTPRS | protein tyrosine phosphatase, receptor type, S | 2.6E-04 | –1.28 | 1.6E-03 | –1.24 | 5.6E-01 | –1.04 |
| RAB3A | RAB3A, member RAS oncogene family | 3.4E-02 | –1.15 | 2.8E-03 | –1.23 | 2.9E-01 | 1.07 |
| RAB6A | RAB6A, member RAS oncogene family | 1.3E-03 | –1.26 | 9.0E-03 | –1.20 | 4.9E-01 | –1.05 |
| RASA1 | RAS p21 protein activator (GTPase activating protein) 1 | 3.6E-02 | –1.15 | 1.3E-02 | –1.19 | 6.3E-01 | 1.03 |
| RGS4 | regulator of G-protein signaling 4 | 1.5E-04 | –1.29 | 1.0E-04 | –1.31 | 8.4E-01 | 1.01 |
| RHOB | ras homolog gene family, member B | 6.8E-03 | –1.20 | 2.0E-02 | –1.17 | 6.8E-01 | –1.03 |
| RORB | RAR-related orphan receptor B | 5.1E-04 | –1.31 | 1.0E-02 | –1.22 | 2.8E-01 | –1.08 |
| RUNX1T1 | runt-related transcription factor 1; translocated to, 1 (cyclin D-related) | 4.7E-02 | –1.14 | 6.0E-04 | –1.27 | 7.8E-02 | 1.12 |
| SFRS3 | splicing factor, arginine/serine-rich 3 | 8.7E-03 | –1.25 | 3.9E-02 | –1.19 | 5.4E-01 | –1.05 |
| SLC3A2 | solute carrier family 3 (activators of dibasic and neutral amino acid transport) | 4.1E-02 | –1.12 | 2.7E-02 | –1.14 | 8.2E-01 | 1.01 |
| SNAP25 | synaptosomal-associated protein, 25 kDa | 4.6E-03 | –1.22 | 1.8E-02 | –1.18 | 6.1E-01 | –1.03 |
| SYN1 | synapsin I | 7.2E-03 | –1.16 | 5.4E-03 | –1.17 | 8.7E-01 | 1.01 |
| THRA | thyroid hormone receptor, alpha (erythroblastic leukemia viral (v-erb-a) oncogen | 2.3E-02 | –1.13 | 7.0E-03 | –1.17 | 5.8E-01 | 1.03 |
| UBAP2L | ubiquitin-associated protein 2-like | 3.7E-02 | –1.16 | 4.5E-02 | –1.15 | 9.5E-01 | –1.00 |
| UBE2D3 | ubiquitin-conjugating enzyme E2D 3 (UBC4/5 homolog, yeast) | 3.8E-03 | –1.25 | 2.5E-02 | –1.19 | 4.6E-01 | –1.05 |
| UBE2S | ubiquitin-conjugating enzyme E2S | 2.7E-02 | –1.15 | 1.6E-02 | –1.17 | 7.9E-01 | 1.02 |
| VDAC1 | voltage-dependent anion channel 1 | 1.0E-02 | –1.15 | 2.2E-02 | –1.14 | 7.7E-01 | –1.02 |
| YWHAZ | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta pol | 1.9E-02 | –1.16 | 1.6E-02 | –1.17 | 9.2E-01 | 1.01 |
| ZNF238 | zinc finger protein 238 | 2.0E-02 | –1.18 | 1.0E-02 | –1.21 | 7.6E-01 | 1.02 |
The 50 normalized genes are shown that fulfilled three criteria on the U95 array. FC = Fold change.